The Annals Holiday Offer - Save 50%
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     



Published Online, 9 July 2008, www.theannals.com, DOI 10.1345/aph.1L079.
The Annals of Pharmacotherapy: Vol. 42, No. 9, pp. 1247-1251. DOI 10.1345/aph.1L079
© 2008 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kupiec, T. C
Right arrow Articles by Patterson, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kupiec, T. C
Right arrow Articles by Patterson, J.

GASTROENTEROLOGY

Physical and Chemical Stability of Esomeprazole Sodium Solutions

Thomas C Kupiec, PhD

Laboratory Director, Analytical Research Laboratories, Oklahoma City, OK

Vasileios Aloumanis, MS

Research Analyst, Analytical Research Laboratories

Michel Ben, MS

Research Analyst, Analytical Research Laboratories

Lawrence A Trissel, BS FASHP

Research Consultant, TriPharma Research, Cashiers, NC

Pak Chan, BS

Research Analyst, Analytical Research Laboratories

Joe Patterson, BS

Research Analyst, Analytical Research Laboratories

Reprints: Mr. Trissel, Research Consultant, c/o TriPharma Research, PO Box 265, Cashiers, NC 28717, fax 828/743-1752, tripharma{at}mail.com

BACKGROUND: Esomeprazole sodium (Nexium IV, AstraZeneca) is the S-isomer of omeprazole and acts as a proton pump inhibitor gastric antisecretory agent indicated for the short-term treatment of gastroesophageal reflux disease in patients with a history of erosive esophagitis. Currently, there is no information on the long-term stability of esomeprazole sodium in infusion solutions beyond 12 hours.

OBJECTIVE: To evaluate the stability of esomeprazole sodium in 5% dextrose, 0.9% sodium chloride, and lactated Ringer's injection, at 2 concentrations, at room temperature and when refrigerated.

METHODS: Triplicate samples of esomeprazole 0.4 and 0.8 mg/mL as the sodium salt were prepared in the solutions required. Stability evaluations were performed initially, over 2 days stored at 23 °C, and over 5 days stored at 4 °C. Physical stability was assessed using turbidimetric and particulate measurement, as well as visual observation. Chemical stability was evaluated by stability-indicating high-performance liquid chromatography.

RESULTS: The samples in all 3 infusion solutions were physically stable throughout the study. None of the samples had evidence of visible haze or particulates. Most samples developed a slight yellow discoloration within 24 hours, but this discoloration was not accompanied by an excessive loss of drug content. The esomeprazole sodium samples in all 3 infusion solutions exhibited less than 7% loss over 2 days at 23 °C and over 5 days at 4 °C.

CONCLUSIONS: Esomeprazole 0.4 and 0.8 mg/mL as the sodium salt in the infusion solutions tested is chemically and physically stable for at least 2 days at room temperature and 5 days under refrigeration.

Key Words: admixture, esomeprazole, stability

Published Online, July 9, 2008. www.theannals.com, DOI 10.1345/aph.1L079


This article has been cited by other articles:


Home page
ANN INTERN MEDHome page
M. A.C. Broeren, E. A.M. Geerdink, H. L. Vader, and A. W. L. van den Wall Bake
Hypomagnesemia Induced by Several Proton-Pump Inhibitors
Ann Intern Med, November 17, 2009; 151(10): 755 - 756.
[Full Text] [PDF]




homecopy help contact us subscription past issues search current issue
Copyright © 2008 by Harvey Whitney Books Company.